



TOPICA ANNOUNCES PARTICIPATION IN UPCOMING INVESTOR CONFERENCES

PALO ALTO, Calif. (October 22, 2009) - TOPICA Pharmaceuticals today announced that Greg Vontz, president and CEO, will present at the following investor conferences next week:

- The 2009 Life Sciences and Healthcare Venture Summit on Tuesday, October 27, at 11:40 a.m. Eastern Time at the Digital Sandbox Network Event Center at 55 Broad Street in New York.
- The 8th Annual BIO Investor Forum on Thursday, October 29 at 9:30 a.m. Pacific Time at the Palace Hotel in San Francisco.

During the presentations, Mr. Vontz will provide an overview of TOPICA and its clinical development progress and plans for luliconazole, one of the most potent and broad spectrum topical antifungal agents, for the treatment of tinea pedis (athlete's foot) and onychomycosis (fungal infections of the nail).

About TOPICA Pharmaceuticals

TOPICA is a privately-held specialty pharmaceutical company focused on licensing, developing and commercializing potent topical prescription products to treat the needs of patients with serious nail and skin conditions. Taking advantage of its established trans-pacific network of scientific and industry contacts, TOPICA has in-licensed its lead product candidate, luliconazole, a topical antifungal agent that is already on the market in Japan. TOPICA is developing luliconazole for the treatment of tinea pedis (athlete's foot) and onychomycosis (fungal infections of the nail). For more information, please visit <http://www.topicapharma.com>.

For more information contact:

Joey Fleury
WeissComm Partners
415-946-1090
jfleury@wcpglobal.com

###